Making dreams a reality Endless challenges and success A new future to come

The R&D Center of Kolon Industries was established in 1978, the first in the chemical fiber industry, and is shaping a new future by strengthening its business portfolio with core technological competitiveness that will drive Kolon's growth.

The R&D Center serves as a hub for convergence research and development to realize the future value of Kolon. In addition, in order to drive sustainable success, the center is conducting ESG-centered R&D and building a global network through collaboration with world-leading companies to continuously discover and promote new business opportunities. Boasting creative and challenging research culture, the R&D Center is striving to strengthen the competitiveness of current businesses through materials development and applied technologies, and to build an R&D network to lay the foundation for future new businesses.

KOLON LIFE SCIENCE BIO Research Center is committed to developing innovative cell and gene therapies based on our vision of becoming a Global Leading Cell & Gene Therapy Company.

To become a global leader in cell and gene therapy, our BIO Research Center focuses on treating neurological disorders and cancer and developing innovative viral carrier-based gene therapies. Subsequent pipelines include treatment for neuropathic pain, KLS-2031 (Phase 1/2a clinical trial in the US), and oncolytic viral therapy, KLS-3021 (preclinical study). We will continue to upgrade our viral carrier platform technology and reinforce our portfolio to secure differentiated capabilities in developing innovative gene therapies.

KOLON LIFE SCIENCE Chemical Research Center will become a leader in APIs and fine chemistry by developing various APIs, intermediates for pharmaceuticals, and antibacterial agents based on our rich experience in synthesis and convergence technologies.

Our Chemical Research Center develops APIs, fine chemicals, and water treatment products. We have successfully entered the Japanese pharmaceutical market by securing a diverse portfolio of APIs and intermediates for pharmaceuticals. We are also growing into a specialized CMO/CDMO company by supplying new clinical drugs and intermediates. Based on the differentiated technologies of our research center, KOLON LIFE SCIENCE is building a competitive process infrastructure, such as catalyst-based process and continuous process development, and supplying antibacterial agents and advanced electrical/electronic materials to domestic and global companies.

The Medical Research Institute focuses research on patient-centered value creation and product competitiveness, and is also expanding the pipeline of differentiated new products and orphan drugs.

The institute identifies research items with business potential and marketability, ensures compliance with development schedules through implementation planning and schedule management, and explores solutions by strengthening its expertise in preparing materials for global-level approvals. It is also expanding its R&D pipeline to enhance future value and actively promoting open innovation to secure new technologies.

The New Drug Development Research Institutes seeks to promote human health through the use of allograft model technology and global-level animal testing and nonclinical evaluation.

The New Drug Development Research Institute has been developing new anti-cancer drugs by identifying more than 60 specific targets such as pancreatic and ovarian cancers. The research is based on an allograft model technology that can accurately evaluate the efficacy and toxicity of new drugs by directly implanting tumors into organs. Researchers who have served as non-clinical / clinical experts in drug development at institutions such as the Anderson Cancer Center are able to dramatically increase the success rate of clinical translation of new drugs by having a variety of cancer models that most closely resemble the tumor tissue of actual patients. In addition to in-house drug development, the center also conducts joint drug development through open innovation with leading domestic and foreign companies.